.

follow-on-google-news

The capital used in the business that is contributed by creditors, shareholders, or owners is measured by the debt-to-equity ratio. The debt-equity ratio, to put it simply, is a ratio of the total amount of long-term debt and equity capital in the company. 

Here are three pharma stocks with a Debt to Equity ratio of zero, indicating that the companies are debt-free, as of March 2024. 

Abbott India Limited 

Abbott India Ltd. offers a wide range of nutritional items based on science, diagnostic tools, branded generic medications, and diabetic and vascular devices. 

With a market capitalisation of Rs. 55,574.8 crore, the share price of Abbott India moved up by 1.08 percent on BSE to hit an intraday high at Rs. 26,341.5 in the trading session of Friday, compared to its previous closing price of Rs. 26,059.9. 

Note: If you want to learn Candlesticks and Chart Trading from Scratch, here’s the best book available on Amazon! Get the book now!

In terms of financials, the company reported a 7.11 percent YoY growth in revenue from operations from Rs. 1,343.08 crore in Q4 FY22-23 to Rs. 1,438.63 crore in Q4 FY23-24. During the same period, net profit increased by 24.04 percent from Rs. 231.42 crore to Rs. 287.06 crore. 

The stock has delivered positive returns of 21.8 percent in the last one year, and 8.7 percent in the last six months. So far in 2024, the company has given 15.06 percent of positive returns. 

Sanofi India Limited 

Sanofi India Limited, formerly known as Aventis Pharma Limited, is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market. 

The company provides a wide range of medicines for therapy areas such as diabetes, cardiology, thrombosis, epilepsy, allergies, infections, vitamins, central nervous system and antihistamines. 

With a market capitalisation of Rs. 20,450.64 crore, the share price of Sanofi India moved up by 1.4 percent on BSE to hit an intraday high at Rs. 9,055.95 in the trading session of Friday, compared to its previous closing price of Rs. 8,926.75. 

In terms of financials, the company reported a 0.55 percent YoY decline in revenue from operations from Rs. 736.5 crore in Q4 FY22-23 to Rs. 732.4 crore in Q4 FY23-24. During the same period, net profit also fell by 28.3 percent from Rs. 190.4 crore to Rs. 136.6 crore.

The stock has delivered positive returns of 38.7 percent in the last one year, and 10.6 percent in the last six months. So far in 2024, the company has given 9.2 percent of positive returns. 

Caplin Point Laboratories Limited 

Incorporated in 1990, Caplin Point Laboratories Limited is a fully integrated Pharma Company and is presently in the business of pharmaceuticals producing, developing and marketing a wide range of generic formulations and branded products and exporting to overseas markets. 

With a market capitalisation of Rs. 9,910.4 crore, the share price of Caplin Point Laboratories moved up by 2.2 percent on BSE to hit an intraday high at Rs. 1,337.95 in the trading session of Friday, compared to its previous closing price of Rs. 1,309.15. 

In terms of financials, the company reported a 16.4 percent YoY growth in revenue from operations from Rs. 389.28 crore in Q4 FY22-23 to Rs. 453.22 crore in Q4 FY23-24. During the same period, net profit increased by 19.7 percent from Rs. 101.24 crore to Rs. 121.23 crore. 

The stock has delivered positive returns of 75.5 percent in the last one year, and 6.3 percent in the last six months. So far in 2024, the company has given 3.7 percent of negative returns.

Written by Shivani Singh

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.